Citations (87)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Shoko Nakayama, Mitsuhiro Matsuda, Tatsuya Adachi, Sanae Sueda, Yuka Ohashi, Sumie Awaji, Shigeo Hashimoto & Itaru Matsumura. (2019) Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era. Platelets 30:5, pages 637-645.
Read now
Read now
Yair Herishanu, Aaron Polliack, Shani Shenhar-Tsarfaty, Ronit Weinberger, Ram Gelman, Tomer Ziv-Baran, David Zeltser, Itzhak Shapira, Sholomo Berliner & Ori Rogowski. (2017) Increased serum C-reactive protein levels are associated with shorter survival and development of second cancers in chronic lymphocytic leukemia. Annals of Medicine 49:1, pages 75-82.
Read now
Read now
Marina Kacevska, Graham R Robertson, Stephen J Clarke & Christopher Liddle. (2008) Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opinion on Drug Metabolism & Toxicology 4:2, pages 137-149.
Read now
Read now
Kellie A. Slaviero, Jane A. Read, Stephen J. Clarke & Laurent P. Rivory. (2003) Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy. Nutrition and Cancer 46:2, pages 148-157.
Read now
Read now
Articles from other publishers (83)
Suat Sincan, Gülden Sincan, Mediha Nur Karaköse, Zekeriya Aksöz & Fuat Erdem. (2023) The Importance of Serum Procalcitonin and C-reactive Protein Levels in Patients with Lymphoma. Meandros Medical and Dental Journal 24:2, pages 168-174.
Crossref
Crossref
Jae‐Hyeon Im, Su‐Min Park, Ju‐Hyun An, Tea‐Hee Kim, Hyung‐Kyu Chae, Ye‐In Oh, Kyoung‐Won Seo & Hwa‐Young Youn. (2023) Evaluation of serum interleukin 2 receptor and beta‐2‐microglobulin as prognostic factors for canine lymphoma: A pilot study. Veterinary and Comparative Oncology 21:2, pages 184-190.
Crossref
Crossref
Marina Knudsen Kirkegaard. (2022) Ocular adnexal lymphoma: Subtype‐specific clinical and genetic features. Acta Ophthalmologica 100:S270, pages 3-37.
Crossref
Crossref
William A. Hall, Theodore G. Karrison, Seth A. Rosenthal, Mahul B. Amin, Leonard G. Gomella, James A. Purdy, A. Oliver Sartor, Jeff M. Michalski, Mark G. Garzotto, Carmen Bergom, Ashesh B. Jani, Colleen A.F. Lawton, Jeffry P. Simko, Joan K. Moore, Elizabeth M. Gore, W. Robert Lee, Paul L. Nguyen, Brita L. Danielson, Howard M. Sandler & Felix Y. Feng. (2022) The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. International Journal of Radiation Oncology*Biology*Physics 114:2, pages 266-274.
Crossref
Crossref
Marco Archetti. (2021) Collapse of Intra-Tumor Cooperation Induced by Engineered Defector Cells. Cancers 13:15, pages 3674.
Crossref
Crossref
Ondřej Škor, Ludmila Bicanová, Birgitt Wolfesberger, Andrea Fuchs‐Baumgartinger, Barbara Ruetgen, Marie Štěrbová, Ilse Schwendenwein & Miriam Kleiter. (2020) Are B‐symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B‐cell lymphoma. Veterinary and Comparative Oncology 19:1, pages 201-208.
Crossref
Crossref
Yanglan Chen, Rong Cong, Chengjian Ji & Wenhua Ruan. (2020) The prognostic role of C‐reactive protein in patients with head and neck squamous cell carcinoma: A meta‐analysis. Cancer Medicine 9:24, pages 9541-9553.
Crossref
Crossref
Antonio Gutierrez, Leyre Bento, Antonio Diaz‐Lopez, Gilberto Barranco, Marta Garcia‐Recio, Armando Lopez‐Guillermo, Ivan Dlouhy, Jordina Rovira, Mario Rodriguez, Jose María Sanchez Pina, Monica Baile, Alejandro Martín, Silvana Novelli, Juan‐Manuel Sancho, Olga García, Antonio Salar, Mariana Bastos‐Oreiro, Mª José Rodriguez‐Salazar, Ruben Fernandez, Fatima Cruz, Jose Antonio Queizan, Sonia González de Villambrosia, Raul Cordoba, Andres López, Hugo Luzardo, Daniel García, Jordi Sastre‐Serra, Juan Fernando Garcia, Carlos Montalban, Fernando Cabanillas & Jose Rodríguez. (2020) Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era. European Journal of Haematology 104:5, pages 400-408.
Crossref
Crossref
Rishav Dasgupta & Shyamasree Ghosh. 2020. Clinical Significance of C-reactive Protein. Clinical Significance of C-reactive Protein
175
192
.
Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae-Woo Jung, Woo-Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye-Ryun Kang, Dong-Wan Kim, Chul Woo Kim & Dae Seog Heo. (2019) Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. The Korean Journal of Internal Medicine 34:4, pages 885-893.
Crossref
Crossref
Zdeněk Král, Zdeněk Adam, František Folber, Mojmír Moulis, Miroslav Tomíška, Lucie Říhová, Martin Štork, Alena Buliková, Luděk Pour, Marta Krejčí, Viera Sandecká, Renata Koukalová, Zdeněk Řehák & Zdenka Čermáková. (2019) Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma. Vnitřní lékařství 65:1, pages 37-44.
Crossref
Crossref
Jing Yang, Zhiqiang Liu, Huan Liu, Jin HeJianling YangPei LinQiang Wang, Juan Du, Wencai MaZheng Yin, Eric Davis, Robert Z. OrlowskiJian Hou & Qing Yi. (2017) C-reactive protein promotes bone destruction in human myeloma through the CD32–p38 MAPK–Twist axis. Science Signaling 10:509.
Crossref
Crossref
Hemendra Ghimire, Mahathi Venkataramani, Zhen Bian, Yuan Liu & A. G. Unil Perera. (2017) ATR-FTIR spectral discrimination between normal and tumorous mouse models of lymphoma and melanoma from serum samples. Scientific Reports 7:1.
Crossref
Crossref
S. J. Fontaine, E. McCulloch, P. D. Eckersall, H. Haining, J. C. Patterson Kane & J. S. Morris. (2017) Evaluation of the modified Glasgow Prognostic Score to predict outcome in dogs with newly diagnosed lymphoma. Veterinary and Comparative Oncology 15:4, pages 1513-1526.
Crossref
Crossref
Ravi Maddaly, Aishwarya Subramaniyan & Harini Balasubramanian. (2017) Cancer Cytokines and the Relevance of 3D Cultures for Studying Those Implicated in Human Cancers. Journal of Cellular Biochemistry 118:9, pages 2544-2558.
Crossref
Crossref
Shasha Shen, Jiaojiao Gong, Yixuan Yang, Si Qin, Lifan Huang, Sha She, Min Yang, Hong Ren & Huaidong Hu. (2017) Molecular mechanism of C-reaction protein in promoting migration and invasion of hepatocellular carcinoma cells in vitro. International Journal of Oncology 50:4, pages 1289-1298.
Crossref
Crossref
Yotaro Ochi, Yasuhiro Kazuma, Nobuhiro Hiramoto, Yuichiro Ono, Satoshi Yoshioka, Noboru Yonetani, Akiko Matsushita, Yukihiro Imai, Hisako Hashimoto & Takayuki Ishikawa. (2016) Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Annals of Hematology 96:1, pages 1-8.
Crossref
Crossref
Kathrine Agergård Kaspersen, Khoa Manh Dinh, Lise Tornvig Erikstrup, Kristoffer Sølvsten Burgdorf, Ole Birger Pedersen, Erik Sørensen, Mikkel Steen Petersen, Henrik Hjalgrim, Klaus Rostgaard, Kaspar Rene Nielsen, Henrik Ullum & Christian Erikstrup. (2016) Low-Grade Inflammation Is Associated with Susceptibility to Infection in Healthy Men: Results from the Danish Blood Donor Study (DBDS). PLOS ONE 11:10, pages e0164220.
Crossref
Crossref
Mayu O. Frank. (2016) Circulating Cell-Free DNA Differentiates Severity of Inflammation. Biological Research For Nursing 18:5, pages 477-488.
Crossref
Crossref
David M. Conrad, David W. Hoskin, Robert Liwski & Christopher Naugler. (2016) A re-examination of the role of the acute phase protein response in innate cancer defence. Medical Hypotheses 93, pages 93-96.
Crossref
Crossref
Hugo J.A. Adams, John M.H. de Klerk, Rob Fijnheer, Ben G.F. Heggelman, Stefan V. Dubois, Rutger A.J. Nievelstein & Thomas C. Kwee. (2015) Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 15:11, pages 671-679.
Crossref
Crossref
Talita Máira Bueno da Silveira da Rocha, Ana Luiza Pereira Miranda Silva, Sérgio Costa Fortier & Carlos Sérgio Chiattone. (2015) Evaluation correlates C-reactive protein with advanced stage Hodgkin's lymphoma and response to treatment in a tertiary university hospital in Brazil. Revista Brasileira de Hematologia e Hemoterapia 37:4, pages 242-246.
Crossref
Crossref
Christina L. Mayer, Lanyi Xie, Rajesh Bandekar, Ming Qi, Helgi van de Velde, Manjula Reddy, Xiang Qin, Hugh M. Davis & Thomas A. Puchalski. (2015) Dose selection of siltuximab for multicentric Castleman’s disease. Cancer Chemotherapy and Pharmacology 75:5, pages 1037-1045.
Crossref
Crossref
Jean-François Rossi, Zhao-Yang Lu, Michel Jourdan & Bernard Klein. (2015) Interleukin-6 as a Therapeutic Target. Clinical Cancer Research 21:6, pages 1248-1257.
Crossref
Crossref
Guillermo Garcia-Manero, Gary Gartenberg, David P. Steensma, Martin R. Schipperus, Dimitri A. Breems, Raquel de Paz, David Valcárcel, Britte Kranenburg, Manjula Reddy & Rami S. Komrokji. (2014) A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome. American Journal of Hematology 89:9, pages E156-E162.
Crossref
Crossref
K T Troppan, K Schlick, A Deutsch, T Melchardt, A Egle, T Stojakovic, C Beham-Schmid, L Weiss, D Neureiter, K Wenzl, R Greil, P Neumeister & M Pichler. (2014) C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. British Journal of Cancer 111:1, pages 55-60.
Crossref
Crossref
Kotaro Hirashima, Masayuki Watanabe, Hironobu Shigaki, Yu Imamura, Satoshi Ida, Masaaki Iwatsuki, Takatsugu Ishimoto, Shiro Iwagami, Yoshifumi Baba & Hideo Baba. (2013) Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer. Journal of Gastroenterology 49:6, pages 1040-1046.
Crossref
Crossref
Yundeok KimSoo Jeong KimDohyu HwangJieun JangShin-Young HyunYu Ri KimJin Seok KimYoo Hong MinJune-Won Cheong. (2014) The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen. Yonsei Medical Journal 55:6, pages 1568.
Crossref
Crossref
A. Softić, L. Begić, A. Halilbašić, T. Vižin & J. Kos. (2013) The Predictive Value of Cystatin C in Monitoring of B Non-Hodgkin Lymphomas: Relation to Biochemical and Clinical Parameters. ISRN Oncology 2013, pages 1-6.
Crossref
Crossref
William A. Hall, Dana C. Nickleach, Viraj A. Master, Roshan S. Prabhu, Peter J. Rossi, Karen Godette, Sherri Cooper & Ashesh B. Jani. (2013) The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate. Cancer 119:18, pages 3272-3279.
Crossref
Crossref
Razelle Kurzrock, Peter M. Voorhees, Corey Casper, Richard R. Furman, Luis Fayad, Sagar Lonial, Hossein Borghaei, Sundar Jagannath, Lubomir Sokol, Saad Z. Usmani, Helgi van de Velde, Xiang Qin, Thomas A. Puchalski, Brett Hall, Manjula Reddy, Ming Qi & Frits van Rhee. (2013) A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clinical Cancer Research 19:13, pages 3659-3670.
Crossref
Crossref
Ya-Jun Li, Zhi-Ming Li, Yi Xia, Jia-Jia Huang, Hui-Qiang Huang, Zhong-Jun Xia, Tong-Yu Lin, Su Li, Xiu-Yu Cai, Zhi-Jun Wu-Xiao & Wen-Qi Jiang. (2013) Serum C-Reactive Protein (CRP) as a Simple and Independent Prognostic Factor in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. PLoS ONE 8:5, pages e64158.
Crossref
Crossref
Ya‐Jun Li, Wen‐Qi Jiang, Jia‐Jia Huang, Zhong‐Jun Xia, Hui‐Qiang Huang & Zhi‐Ming Li. (2013) The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T‐cell lymphoma, nasal type. American Journal of Hematology 88:5, pages 394-399.
Crossref
Crossref
Lucia Pacifico, John F. Osborn, Fabio Natale, Flavia Ferraro, Mario De Curtis & Claudio Chiesa. 2013.
203
263
.
Qing Yi. 2013. Advances in Biology and Therapy of Multiple Myeloma. Advances in Biology and Therapy of Multiple Myeloma
25
42
.
Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, Lance Leopold, Matthew D. Galsky & Guru Sonpavde. (2012) Ability of C‐reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel‐based chemotherapy. BJU International 110:11b.
Crossref
Crossref
Akiyoshi Kinoshita, Hiroshi Onoda, Keiko Takano, Nami Imai, Chisato Saeki, Nao Fushiya, Yoshinari Miyakawa, Hirokazu Nishino & Hisao Tajiri. (2012) Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Medical Oncology 29:4, pages 2800-2808.
Crossref
Crossref
Marco La Torre, Giuseppe Nigri, Marco Cavallini, Paolo Mercantini, Vincenzo Ziparo & Giovanni Ramacciato. (2012) The Glasgow Prognostic Score as a Predictor of Survival in Patients with Potentially Resectable Pancreatic Adenocarcinoma. Annals of Surgical Oncology 19:9, pages 2917-2923.
Crossref
Crossref
Ye Cao, Yan-xia Shi, Jing-ou Chen, Yu-ting Tan, Yu-Chen Cai, Hui-yan Luo, Miao-zhen Qiu, Xiu-yu Cai, Ying Jin, Yue-li Sun & Wen-qi Jiang. (2012) Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumor Biology 33:4, pages 1039-1044.
Crossref
Crossref
Ho-Jin Shin, Joo Seop Chung, Moo-Kon Song, Seon-Kyeong Kim, Sangmin Choe & Goon-Jae Cho. (2012) Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. Cancer Chemotherapy and Pharmacology 69:5, pages 1165-1172.
Crossref
Crossref
Renee C. Prins, Brooks L. Rademacher, Solange Mongoue-Tchokote, Joshi J. Alumkal, Julie N. Graff, Kristine M. Eilers & Tomasz M. Beer. (2012) C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Urologic Oncology: Seminars and Original Investigations 30:1, pages 33-37.
Crossref
Crossref
Jun-Eul Hwang, Ha-Na Kim, Dae-Eun Kim, Hyun-Jung Choi, Sung-Hoon Jung, Hyun-Jeong Shim, Woo-Kyun Bae, Eu-Chang Hwang, Sang-Hee Cho & Ik-Joo Chung. (2011) Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer 11:1.
Crossref
Crossref
Jiří Pavlů, Holger W. Auner, Sarah Ellis, Richard M. Szydlo, Chrissy Giles, Alejandro Contento, Amin Rahemtulla, Jane F. Apperley, Kikkeri Naresh, Donald H. MacDonald & Edward J. Kanfer. (2011) LACE‐conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B‐cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematological Oncology 29:2, pages 75-80.
Crossref
Crossref
Nathan Fowler & Peter McLaughlin. 2011. Advances in Malignant Hematology. Advances in Malignant Hematology
274
295
.
R. KANZ, T. VUKOVICH, R. VORMITTAG, D. DUNKLER, C. AY, J. THALER, J. HASELBÖCK, W. SCHEITHAUER, C. ZIELINSKI & I. PABINGER. (2011) Thrombosis risk and survival in cancer patients with elevated C‐reactive protein. Journal of Thrombosis and Haemostasis 9:1, pages 57-63.
Crossref
Crossref
Yong Park, Dae Sik Kim, Seh Jong Park, Hee Yun Seo, Se Ryeon Lee, Hwa Jung Sung, Kyong Hwa Park, In Keun Choi, Seok Jin Kim, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim & Jun Suk Kim. (2010) The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. Leukemia Research 34:3, pages 294-300.
Crossref
Crossref
Otoniel Martínez-Maza, Alan Duane Moreno & Wendy Cozen. 2010. Cancer and IgE. Cancer and IgE
79
136
.
Rohini Sharma, David Cunningham, Paul Smith, Graham Robertson, Owen Dent & Stephen J Clarke. (2009) Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer 9:1.
Crossref
Crossref
Marta Planellas, Anna Bassols, Carlo Siracusa, Yolanda Saco, Mercè Giménez, Raquel Pato & Josep Pastor. (2009) Evaluation of serum haptoglobin and C-reactive protein in dogs with mammary tumors. Veterinary Clinical Pathology 38:3, pages 348-352.
Crossref
Crossref
Rom Keshet, Ben Boursi, Ramit Maoz, Matti Shnell & Hanan Guzner-Gur. (2009) Diagnostic and Prognostic Significance of Serum C-Reactive Protein Levels in Patients Admitted to the Department of Medicine. The American Journal of the Medical Sciences 337:4, pages 248-255.
Crossref
Crossref
Jun Ah Lee, Min Suk Kim, Dong Ho Kim, Jung Sub Lim, Kyung Duk Park, Wan Hyeong Cho, Won Seok Song, Soo-Yong Lee & Dae-Geun Jeon. (2009) Postoperative Infection and Survival in Osteosarcoma Patients. Annals of Surgical Oncology 16:1, pages 147-151.
Crossref
Crossref
Jun-ichi Kitagawa, Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Toshiki Yamada, Michio Sawada, Takeshi Takahashi, Masahito Shimizu, Tsuyoshi Takami & Hisataka Moriwaki. (2008) Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). Journal of Cancer Research and Clinical Oncology 135:1, pages 53-59.
Crossref
Crossref
Nathan A Stephens, Richard JE Skipworth & Kenneth CH Fearon. (2008) Cachexia, survival and the acute phase response. Current Opinion in Supportive & Palliative Care 2:4, pages 267-274.
Crossref
Crossref
Hans Jürgen Dornbusch, Volker Strenger, Petra Sovinz, Herwig Lackner, Wolfgang Schwinger, Reinhold Kerbl & Christian Urban. (2008) Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders. Supportive Care in Cancer 16:9, pages 1035-1040.
Crossref
Crossref
Tomasz M. Beer, Alshad S. Lalani, Stella Lee, Motomi Mori, Kristine M. Eilers, John G. Curd, W. David Henner, Christopher W. Ryan, Peter Venner, J. Dean Ruether & Kim N. Chi. (2008) C‐reactive protein as a prognostic marker for men with androgen‐independent prostate cancer. Cancer 112:11, pages 2377-2383.
Crossref
Crossref
Lise Nielsen, Nils Toft, P. David Eckersall, Dominic J. Mellor & Joanna S. Morris. (2008) Serum C‐Reactive Protein Concentration as an Indicator of Remission Status in Dogs with Multicentric Lymphoma. Journal of Veterinary Internal Medicine 21:6, pages 1231-1236.
Crossref
Crossref
Jing Yang, Michele Wezeman, Xiang Zhang, Pei Lin, Michael Wang, Jianfei Qian, Bo Wan, Larry W. Kwak, Long Yu & Qing Yi. (2007) Human C-Reactive Protein Binds Activating Fcγ Receptors and Protects Myeloma Tumor Cells from Apoptosis. Cancer Cell 12:3, pages 252-265.
Crossref
Crossref
Murat Bolayırlı, Hande Turna, Timur Orhanoğlu, Resat Ozaras, Mahmut İlhan & Mustafa Özgüroğlu. (2007) C-reactive protein as an acute phase protein in cancer patients. Medical Oncology 24:3, pages 338-344.
Crossref
Crossref
Yair Herishanu, Chava Perry, Rony Braunstein, Ur Metser, Odelia Goor, Ori Rogowski, Shlomo Berliner, Aaron Polliack & Elizabeth Naparstek. (2007) Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin?s lymphoma. European Journal of Haematology 79:2, pages 150-154.
Crossref
Crossref
L Kelly, S White & P.C. Stone. (2007) The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study. Annals of Oncology 18:8, pages 1395-1399.
Crossref
Crossref
R. Mischke, M. Waterston & P.D. Eckersall. (2007) Changes in C-reactive protein and haptoglobin in dogs with lymphatic neoplasia. The Veterinary Journal 174:1, pages 188-192.
Crossref
Crossref
Sang-Yeon Suh & Hong-Yup Ahn. (2007) A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients. Supportive Care in Cancer 15:6.
Crossref
Crossref
Alexandre Merlo, Bárbara Cristina Gagliano Rezende, Maria Luisa Franchini, Denise Maria Nunes Simões & Sílvia Regina Ricci Lucas. (2007) Serum C-reactive protein concentrations in dogs with multicentric lymphoma undergoing chemotherapy. Journal of the American Veterinary Medical Association 230:4, pages 522-526.
Crossref
Crossref
A Zahlten-Hinguranage, H Goldschmidt, F W Cremer, G Egerer, T Moehler, D Witte, L Bernd, D Sabo & F Zeifang. (2006) Preoperative elevation of serum C – reactive protein is predictive for prognosis in myeloma bone disease after surgery. British Journal of Cancer 95:7, pages 782-787.
Crossref
Crossref
F. Tecles, E. Spiranelli, U. Bonfanti, J.J. Cerón & S. Paltrinieri. (2005) Preliminary Studies of Serum Acute-Phase Protein Concentrations in Hematologic and Neoplastic Diseases of the Dog. Journal of Veterinary Internal Medicine 19:6, pages 865-870.
Crossref
Crossref
Diana LithgowChandice Covington. (2016) Chronic Inflammation and Breast Pathology: A Theoretical Model. Biological Research For Nursing 7:2, pages 118-129.
Crossref
Crossref
Angelo Nespoli, Luca Gianotti, Mauro Totis, Giorgio Bovo, Luca Nespoli, Paolo Chiodini & Ferdinando Brivio. (2018) Correlation between Postoperative Infections and Long-term Survival after Colorectal Resection for Cancer. Tumori Journal 90:5, pages 485-490.
Crossref
Crossref
James T. Wu. 2004. Cancer Diagnostics. Cancer Diagnostics
65
84
.
D. Barry Boyd. (2016) Insulin and Cancer. Integrative Cancer Therapies 2:4, pages 315-329.
Crossref
Crossref
Richard A Krasuski, Anneke Bush, Joseph E Kay, Charles E MayesJrJr, Andrew Wang, Judy Fleming, Cynthia Pierce, Katherine B Kisslo, J.Kevin Harrison & Thomas M Bashore. (2003) C-reactive protein elevation independently influences the procedural success of percutaneous balloon mitral valve commissurotomy. American Heart Journal 146:6, pages 1099-1104.
Crossref
Crossref
H J Dornbusch, V Strenger, R Kerbl, H Lackner, W Schwinger, P Sovinz & C Urban. (2003) Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-T-lymphocyte antibodies and Gram-negative sepsis. Bone Marrow Transplantation 32:9, pages 941-945.
Crossref
Crossref
Annemarie Wieland, Reinhold Kerbl, Andrea Berghold, Wolfgang Schwinger, Georg Mann & Christian Urban. (2003) C‐reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Medical and Pediatric Oncology 41:1, pages 21-25.
Crossref
Crossref
Yuan-Chang Chung & Ya-Fen Chang. (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. European Journal of Gastroenterology & Hepatology 15:4, pages 369-373.
Crossref
Crossref
Lars Møller Pedersen & Peter Grundtvig Sørensen. (2003) Mediators of inflammation correlate with microalbuminuria in patients with non-Hodgkin's lymphoma. British Journal of Haematology 121:2, pages 275-279.
Crossref
Crossref
Mehmet Koc, Seyithan Taysi, Orhan Sezen & Nuri Bakan. (2003) Levels of some Acute-Phase Proteins in the Serum of Patients with Cancer during Radiotherapy. Biological and Pharmaceutical Bulletin 26:10, pages 1494-1497.
Crossref
Crossref
Heinz Baumann. 2003. Signal Transducers and Activators of Transcription (STATs). Signal Transducers and Activators of Transcription (STATs)
465
491
.
S J Wigmore, A J MacMahon, C M Sturgeon & K C H Fearon. (2001) Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. British Journal of Surgery 88:2, pages 255-260.
Crossref
Crossref
Fade Aziz Mahmoud & Nilo I. Rivera. (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Current Oncology Reports 4:3, pages 250-255.
Crossref
Crossref
E Kovacs & J.J Kuehn. (2002) Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does Viscum album treatment affect these parameters?. Biomedicine & Pharmacotherapy 56:3, pages 152-158.
Crossref
Crossref
Mustafa Cengiz, Serap Akbulut, I.Lale Atahan & Perry W Grigsby. (2001) Acute phase response during radiotherapy. International Journal of Radiation Oncology*Biology*Physics 49:4, pages 1093-1096.
Crossref
Crossref
L. Benboubker, C. Valat, C. Linassier, G. Cartron, M. Delain, M. Bout, F. Fetissof, T. Lefranq, J.P. Lamagnere & Ph. Colombat. (2000) A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels. Annals of Oncology 11:11, pages 1485-1491.
Crossref
Crossref
N. Penel, M. Degardin, F. Frippiat & E. Hachulla. (2000) Existe-t-il des critères diagnostiques en faveur d'une fièvre paranéoplasique ?. La Revue de Médecine Interne 21:8, pages 684-692.
Crossref
Crossref
Takeshi Hara, Hisashi Tsurumi, Masao Takemura, Hideko Goto, Toshiki Yamada, Michio Sawada, Takeshi Takahashi & Hisataka Moriwaki. (2000) Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. American Journal of Hematology 64:4, pages 257-261.
Crossref
Crossref